On Nov. 13, 2019, researchers at University of California San Diego (UCSD) School of Medicine announced that they had successfully applied phage therapy in mice to treat alcohol-related liver disease, targeting cytolytic E. faecalis, providing a method to precisely edit the gut microbiome and offering new treatment for patients with severe alcoholic hepatitis.